Literature DB >> 28900843

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Procedure for Non-resectable Peritoneal Carcinomatosis (with Video).

Jean-Baptiste Cazauran1, Mohammad Alyami2,3,4,5, Antoinette Lasseur1, Isabo Gybels1,6, Olivier Glehen1,7, Naoual Bakrin1,7.   

Abstract

BACKGROUND: Peritoneal carcinomatosis (PC) is a common evolution of abdominal cancers and is associated with poor prognosis in the absence of aggressive multimodal therapy.1 Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a safe and innovative approach, which enhances the effect of chemotherapy 2 without reported renal/hepatic toxicity.3,4 It requires mastery of technical aspects to reduce postoperative morbidity, increase effectiveness, and prevent caregiver chemotherapy exposure. We, therefore, report herein the surgical protocol after 2 years of implementation in our university center specialized in PC management, accompanied by a short video, to share our experience.
METHODS: The procedure was performed under general anesthesia and capnoperitoneum (12 mmHg, 37 °C) using two balloon trocars placed in the midline, in accordance with the open laparoscopic technique. Explorative laparoscopy allowed Sugarbaker peritoneal cancer index to be determined. Parietal biopsies were taken, and ascites was removed for peritoneal cytology. The nebulizer was inserted and connected to a high-pressure injector. A pressurized aerosol containing chemotherapy agents was then administered; cisplatin (7.5 mg/m2 in 150 ml 0.9%NaCl) immediately followed by doxorubicin (1.5 mg/m2 in 50 ml 0.9%NaCl), or oxaliplatin alone (92 mg/m2 in 150 ml 0.9%NaCl), based on PC origin and chemotherapy history. The aerosol was kept in a steady-state for 30 min then exhausted through a closed filter system, and trocars were retracted. Each step is illustrated in the video.
CONCLUSION: This video protocol provides a better understanding of the PIPAC procedure and the safety measures essential for this method of chemotherapy administration. It should help all teams wishing to implement a PIPAC therapy program.

Entities:  

Keywords:  Medical device; Peritoneal metastases; Protective equipment; Safety procedure; Surgical protocol

Mesh:

Substances:

Year:  2017        PMID: 28900843     DOI: 10.1007/s11605-017-3565-0

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  4 in total

1.  Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.

Authors:  B Sadeghi; C Arvieux; O Glehen; A C Beaujard; M Rivoire; J Baulieux; E Fontaumard; A Brachet; J L Caillot; J L Faure; J Porcheron; J L Peix; Y François; J Vignal; F N Gilly
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

2.  Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy.

Authors:  Wiebke Solass; Reinhold Kerb; Thomas Mürdter; Urs Giger-Pabst; Dirk Strumberg; Clemens Tempfer; Jürgen Zieren; Matthias Schwab; Marc André Reymond
Journal:  Ann Surg Oncol       Date:  2013-09-05       Impact factor: 5.344

3.  Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Authors:  Ana Blanco; Urs Giger-Pabst; Wiebke Solass; Jürgen Zieren; Marc A Reymond
Journal:  Ann Surg Oncol       Date:  2013-02-03       Impact factor: 5.344

4.  Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects.

Authors:  Wiebke Solass; Urs Giger-Pabst; Jürgen Zieren; Marc A Reymond
Journal:  Ann Surg Oncol       Date:  2013-06-14       Impact factor: 5.344

  4 in total
  6 in total

1.  Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.

Authors:  Abdelkader Taibi; Olivia Sgarbura; Martin Hübner; Sylvia M Bardet; Mohammed Alyami; Naoual Bakrin; Sylvaine Durand Fontanier; Clarisse Eveno; Johan Gagniere; Basile Pache; Marc Pocard; François Quenet; Hugo Teixeira Farinha; Emilie Thibaudeau; Frederic Dumont; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2022-03-22       Impact factor: 4.339

2.  Staging laparoscopy and Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for peritoneal metastasis: safe access to the abdomen.

Authors:  Torben Glatz; Philipp Horvath; Sven A Lang; Rami Archid; Giorgi Nadiradze
Journal:  Pleura Peritoneum       Date:  2019-03-21

3.  Overall clinical and trichoscopic analysis performed in patients who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment for peritoneal carcinomatosis - initial trial preliminary report.

Authors:  Maciej Nowacki; Katarzyna Nowacka; Iwona Głowacka; Barbara Zegarska; Wojciech Zegarski
Journal:  Postepy Dermatol Alergol       Date:  2019-08-30       Impact factor: 1.837

4.  Consensus statement on safety measures for pressurized intraperitoneal aerosol chemotherapy.

Authors:  Arnaud Girardot-Miglierina; Daniel Clerc; Mohammad Alyami; Laurent Villeneuve; Olivia Sgarbura; Marc-André Reymond; Martin Hübner
Journal:  Pleura Peritoneum       Date:  2021-11-02

Review 5.  Review of Regional Therapies for Gastric Cancer with Peritoneal Metastases.

Authors:  Beatrice J Sun; Byrne Lee
Journal:  Cancers (Basel)       Date:  2022-01-23       Impact factor: 6.639

6.  COVID-19: impact on colorectal surgery.

Authors:  S D Wexner; D Cortés-Guiral; H Gilshtein; I Kent; M A Reymond
Journal:  Colorectal Dis       Date:  2020-05-22       Impact factor: 3.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.